Jubilant Pharmova Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 16,608.7 million compared to INR 15,144.4 million a year ago. Revenue was INR 16,824.5 million compared to INR 15,245.7 million a year ago. Net loss was INR 978.4 million compared to net income of INR 595.5 million a year ago. Basic loss per share from continuing operations was INR 6.15 compared to basic earnings per share from continuing operations of INR 3.74 a year ago. Diluted loss per share from continuing operations was INR 6.15 compared to diluted earnings per share from continuing operations of INR 3.74 a year ago.
For the full year, sales was INR 62,193 million compared to INR 60,591.7 million a year ago. Revenue was INR 63,200.6 million compared to INR 61,414.5 million a year ago. Net loss was INR 609.8 million compared to net income of INR 4,139.4 million a year ago. Basic loss per share from continuing operations was INR 3.83 compared to basic earnings per share from continuing operations of INR 26 a year ago. Diluted loss per share from continuing operations was INR 3.83 compared to diluted earnings per share from continuing operations of INR 26 a year ago.